Primex Pharmaceuticals
Primex is a modern streamlined pharma company in operation since early 2008. It is
headquartered in Finland and Switzerland and operates around the world.
Products are contract manufactured for Primex by Bayer and other world-class manufacturers in
the EU.
Primex is now present in about 35 countries from Mexico to Indonesia to New Zealand. The
distribution network covers a population of nearly one billion people. This world-wide Primex
sales and distribution organization is greatly contributing to the attractiveness of Primex and will
thus speeding up the additional international acquisitions and partnerships.
Primex recently acquired two global businesses and brands, Dobuject
(dobutamine) in 2009, and Recofol (propofol) in 2010, consisting of distribution agreements,
marketing authorizations, trademarks, dossiers etc. The former is now manufactured for Primex
by Bayer under a contract manufacturing agreement on a new dedicated manufacturing site
started January 2010. The latter is produced on two other sites inside the EU.
The Recofol acquisition included also the propofol factory production line (previously owned by
Bayer and Santen) and related equipment for the production of Recofol (and propofol and other
fat emulsions). The line is removed and prepared for transport and relocation to one of the three
non-EU production sites under consideration. Primex is negotiating to sell the production line
along with related production and marketing rights with the opportunity to sell Recofol products
back to Primex for its global distribution. The change in the production domicile will cut costs
considerably. These negotiations are expected to be concluded by the end of 2011. These
improvements will open an array of new international opportunities for Primex.
World Class Brands: Dobuject and Recofol
Dobuject and Recofol are both strong Bayer brands in the categories of cardilology, anesthesia
and intensive care.
Dobuject is indicated for acute cardiac failure and it is typically used in the hospital intensive
care units. It has been improved considerably from the first dobutamine on the market, and it is
the only one with no preservatives other than vitamin C.
Recofol is an intravenous anesthetic also typically used by the intensive care units. It is known
for its versatility, quality, speed, and lack of uncomfortable side effects such as post-operative
nausea.
Recofol can be used from a light sedation to a full coma as needed; it is used in fixing an off-set
knee cap as well as in a case of serious brain damage.
The sales of both products have been either stable or slightly growing.
Primex has grown the sales of Dobuject by 40 % vs budget in 2010 as a result of its efforts
during the spring of 2010. In general, the market for dobutamine is mature, while the market for
propofol is growing due to the changes in patient care (e.g. a worldwide trend to increase day
surgery). There are substantial possibilities to grow the sales through close partnerships, joint
ventures, effective distributors and by expanding to completely new markets. Several regions in
the world are looking for these cost-efficient Western medications as their health care develops.
Primex is presently pursuing to acquire more businesses and products.
There is an onchology product from a Big Pharma as another anesthetics under final
negotiations.
The Primex sales and distribution network is a unique resource and power in acquisitions; it
consists of some of the strongest regional pharmaceutical companies (e.g. PiSA, the leading
pharma company in Central America with its 10 000 employees in the region, while teh
Indonesian Dexa Medica is among the top five ASEAN pharma companies). In order to
guarantee sufficient funds to finance the acquisitions and to grow the company faster, Primex
succesfully rased capital with the help of a major North European investment bank in early 2011.
There are now over 10 shareholders, including the Finnish government through a fund.
Contact information:
Kari Sarvanto
CEO
Gsm +358 400 602089
Primex Pharmaceuticals Ltd
Eteläesplanadi 24
FI-00130 Helsinki
Finland